drugset / Trial / NCT05057806
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Phase 0
Recruiting
30 enrolled
The University of Texas Health Science Center at San Antonio
Doris Duke Charitable Foundation · collabMax and Minnie Tomerlin Voelcker Fund · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Timeline
- Start
- 2021-01-13
- Primary completion
- 2026-11-30
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | Oral |